Improvement in Morning Akinesia After Foslevodopa/Foscarbidopa Treatment was Associated with Significantly Improved Motor Fluctuations, Activities of Daily Living, and Quality of Life in People with Parkinson’s Disease (S37.004)
Assessment of morning akinesia (MA) association with motor complications, activities of daily living (ADL), quality of life (QoL), and sleep in patients with advanced Parkinson’s disease (PD) receiving continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp).
Authors
- Diego Santos‐García (ORCID: https://orcid.org/0000-0002-3126-5111)
- Rajesh Pahwa (ORCID: https://orcid.org/0000-0003-3176-6466)
- Megha Shah (ORCID: https://orcid.org/0000-0002-6722-7846)
- Lars Bergmann (ORCID: https://orcid.org/0000-0002-8603-8549)
- Angelo Antonini (ORCID: https://orcid.org/0000-0003-1040-2807)
- Sara Dhanani
- Okeanis Vaou (ORCID: https://orcid.org/0000-0003-0453-3077)
- Bruno Bergmans (ORCID: https://orcid.org/0000-0002-1463-8262)
- Thomas Kimber (ORCID: https://orcid.org/0000-0002-6496-7400)
- Resmi Gupta (ORCID: https://orcid.org/0000-0001-6552-4372)
- Linda Harmer
Institutions
- Royal Adelaide Hospital (AU)
- University of Padua (IT)
- The University of Texas at San Antonio Health Science Center (US)
- Ghent University Hospital (BE)
- AbbVie (United States) (US)
- AZ Sint-Jan (BE)
- University of Kansas Medical Center (US)
- Complexo Hospitalario Universitario A Coruña (ES)
- Banner Sun Health Research Institute (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208656
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39